ReviewInternational journal of women's health2015
Complications and challenges associated with polycystic ovary syndrome: current perspectives.
Review in International journal of women's health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 7 syntheses or guidelines pooled it, 264 citations in OpenAlex.
- Polycystic ovary syndrome and risk of endometrial hyperplasia and endometrial cancer in women with abnormal uterine bleeding: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
- Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association between exposure to endocrine-disrupting chemicals and polycystic ovary syndrome: a systematic review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Pooled it
- Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis.Human reproduction (Oxford, England) · 2023Pooled it
- Mechanistic and therapeutic insight into the effects of cinnamon in polycystic ovary syndrome: a systematic review.Journal of ovarian research · 2021Pooled it
- Pooled it
- Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies.Frontiers in cardiovascular medicine · 2020Pooled it
- Effect of Probiotic Supplementation on Reproductive Outcomes of Women With Polycystic Ovary Syndrome Who Are Candidates for Intrauterine Insemination: A Randomized, Double-Blind, Placebo-Controlled Trial.Endocrinology, diabetes & metabolism · 2026Trial
- The effect of synbiotics supplementation on anthropometric indicators and lipid profiles in women with polycystic ovary syndrome: a randomized controlled trial.Lipids in health and disease · 2020Trial
- Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS).International journal of medical sciences · 2015Trial
- Systems genetics approaches model the heritable architecture of polyendocrine metabolic ovarian syndrome.The Journal of clinical investigation · 2026Article
- The Effect of Polycystic Ovarian Syndrome on Development of Diabetes Mellitus by a Multistate Modelling Approach.Endocrinology, diabetes & metabolism · 2026Article
- Association Between Polycystic Ovary Syndrome and Markers of Subclinical Atherosclerosis in Premenopausal Women: A Systematic Review.Journal of clinical medicine · 2026Review
- Predictors of Hypertensive Disorders of Pregnancy in Japan: A Population-Based Retrospective Cohort Study Using the Shizuoka Kokuho Database.The journal of obstetrics and gynaecology research · 2026Article
- Prevalence and Clinical Features of Polyendocrine Metabolic Ovarian Syndrome in the Gulf Cooperation Council Countries: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- The Bushen Huatan formula inhibits TP53-Mediated ferroptosis and modulating lipid metabolism in polycystic ovary syndrome abnormalities rat model.Journal of ovarian research · 2026Article
- Review
- Assessment of Sonographic Ovarian Volume as an Potential Predictor of Polycystic Ovarian Syndrome (PCOS): A Hospital-Based Cross-Sectional StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- Exploring the comorbidity of type 2 diabetes mellitus and polycystic ovary syndrome: treatment with traditional Chinese medicine.Frontiers in medicine · 2026Review
- Effects of different durations of high-intensity interval training or continuous training with/without metformin on lipid profile and malondialdehyde level in a rat model of polycystic ovary syndrome.Veterinary research forum : an international quarterly journal · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) represents the most common endocrine dysfunction in fertile women and it is considered a heterogeneous and multifaceted disorder, with multiple reproductive and metabolic phenotypes which differently affect the early- and long-term syndrome's risks. Women with PCOS present an adverse reproductive profile, including a high risk of pregnancy-induced hypertension, preeclampsia, and gestational diabetes mellitus. Patients with PCOS present not only a higher prevalence of classic cardiovascular risk factors, such as hypertension, dyslipidemia, and type-2 diabetes mellitus, but also of nonclassic cardiovascular risk factors, including mood disorders, such as depression and anxiety. Moreover, at the moment, clinical data on cardiovascular morbidity and mortality in women with PCOS are controversial. Finally, women with PCOS show an increased risk of endometrial cancer compared to non-PCOS healthy women, particularly during premenopausal period. Currently, we are unable to clarify if the increased PCOS early- and long-term risks are totally due to PCOS per se or mostly due to obesity, in particular visceral obesity, that characterized the majority of PCOS patients. In any case, the main endocrine and gynecological scientific societies agree to consider women with PCOS at increased risk of obstetric, cardiometabolic, oncology, and psychological complications throughout life, and it is recommended that these women be accurately assessed with periodic follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.